Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says.
06:00am, Thursday, 08'th Apr 2021
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
04:01pm, Tuesday, 06'th Apr 2021
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat
Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection
09:08am, Monday, 05'th Apr 2021
Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibod
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –
Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients
09:32am, Monday, 29'th Mar 2021
Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlaniv
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)
04:23am, Monday, 29'th Mar 2021
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)
GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug
12:42pm, Friday, 26'th Mar 2021
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an inve
GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatment
08:40am, Friday, 26'th Mar 2021
GlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
01:03am, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
10:29pm, Sunday, 21'st Mar 2021
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors a
Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline
01:00pm, Sunday, 21'st Mar 2021
Short-term investors may not see the long-term potential.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
05:13pm, Thursday, 18'th Mar 2021
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advi
Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner
11:47am, Wednesday, 17'th Mar 2021
Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GS
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast)
11:00am, Wednesday, 17'th Mar 2021
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast)
